Excessive Daytime Sleepiness EDS Diagnosis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Excessive Daytime Sleepiness (EDS) Diagnosis Market is segemented By Drug Type (Stimulants, Orexin Receptor Antagonists, Antidepressants, Others), By Indication (Narcolepsy, Obstructive Sleep Apnea (OSA), Shift Work Sleep Disorder (SWSD), Idiopathic Hypersomnia), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Excessive Daytime Sleepiness EDS Diagnosis Market Size
Market Size in USD
CAGR9.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 9.2% |
| Market Concentration | Medium |
| Major Players | Jazz Pharmaceuticals, Takeda Pharmaceutical Company, Harmony Biosciences, Avadel Pharmaceuticals, Bioprojet Pharma |
please let us know !
Excessive Daytime Sleepiness EDS Diagnosis Market Analysis
The excessive daytime sleepiness (EDS) diagnosis market is estimated to be valued at USD 6.8 billion in 2024 and is expected to reach USD 12.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
The excessive daytime sleepiness (EDS) diagnosis market is growing at a steady rate due to the increasing awareness about sleep disorders and their diagnosis. Rise in lifestyle diseases globally is also leading to increased chances of developing sleep problems.